BindingDB logo
myBDB logout

47 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27692854 100 N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.EBI Boehringer Ingelheim Pharmaceuticals
25101488 50 Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.EBI Bristol Myers Squibb Company
24332486 35 Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.EBI AstraZeneca
23707259 98 The discovery of BMS-457, a potent and selective CCR1 antagonist.EBI Bristol-Myers Squibb Company
23659855 36 Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.EBI AstraZeneca
23414842 16 Spirocyclic compounds, potent CCR1 antagonists.EBI AstraZeneca
23374868 76 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.EBI ChemoCentryx, Inc.
20627722 89 Identification of a sulfonamide series of CCR2 antagonists.EBI GlaxoSmithKline Medicines Research Centre
23142617 57 Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.EBI AstraZeneca
23079519 86 In vivo activity of an azole series of CCR2 antagonists.EBI GlaxoSmithKline Research and Development
22957890 174 Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.EBI University of Copenhagen
23075267 85 Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.EBI Bristol-Myers Squibb Company
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
18313297 107 Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.EBI Deltagen Research Laboratories (Former CombiChem, Inc.
18329267 136 Identification of novel series of human CCR1 antagonists.EBI Tanabe Research Laboratories USA, Inc.
17483457 58 A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.EBI Abbott Laboratories
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
10579830 98 Discovery of novel non-peptide CCR1 receptor antagonists.EBI Berlex Biosciences
14505678 21 Design and synthesis of novel CCR3 antagonists.EBI Roche Palo Alto
22104149 1 Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.EBI University of Kansas
22047688 51 CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.EBI GlaxoSmithKline
21940167 12 Design and synthesis of a library of chemokine antagonists.EBI Novartis Institutes of Biomedical Research
21341682 37 Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.EBI Telik, Inc.
20708929 13 Novel pyrrolidine heterocycles as CCR1 antagonists.EBI Ligand Pharmaceuticals, Inc.
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
19183043 36 Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.EBI Pharmacopeia, Inc.
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
17446072 68 Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.EBI Tanabe Research Laboratories, Inc.
17383873 10 Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.EBI Pfizer Global Research and Development
16698264 37 Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.EBI Merck Research Laboratories
16539392 29 Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.EBI Takeda Pharmaceutical Company Limited
15771462 125 Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.EBI Pharmaceutical Research Institute
15081003 38 Novel CCR1 antagonists with improved metabolic stability.EBI Pfizer Global Research and Development
15081002 33 Potent small molecule CCR1 antagonists.EBI Pfizer Global Research and Development
15081001 17 The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.EBI Pfizer Global Research and Development
12166951 146 Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.EBI Bristol-Myers Squibb Company
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11354381 19 Discovery of a novel CCR3 selective antagonist.EBI Banyu Tsukuba Research Institute
11311066 76 Design, synthesis, and discovery of a novel CCR1 antagonist.EBI Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories
11206474 51 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.EBI Merck Research Laboratories
11140734 8 Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds.EBI National Cancer Istitute-Frederick Cancer Research and Development Center
10821717 29 Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.EBI Takeda Chemical Industries, Ltd.